If you have IBD and are taking or considering a GLP‑1 drug for obesity or diabetes, this large claims-based study did not find that those drugs lowered the risk of IBD relapse — so they shouldn’t be expected to improve...

High and rising out-of-pocket costs can force people with Crohn’s disease to worry about medical debt, skip care, or make major life changes. Policy choices about insurance coverage (like Medicaid expansion) can...

A new bispecific antibody program (TL1A x IL-23p19) advancing toward patient trials could expand treatment options for people with ulcerative colitis and Crohn’s disease if later-stage trials confirm safety and efficacy....

The study identifies berberine as a compound that reduced epithelial pyroptosis and improved disease markers in a mouse model of bacterial colitis, suggesting a possible new mechanism-target for colitis therapies. This...

Fear of movement was substantially more common and often more severe in people with Crohn’s disease in this study, which could act as a barrier to exercise and rehabilitation. Addressing kinesiophobia may help improve...

If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...

This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...

A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...

The study describes a new investigational bispecific antibody that reduced T-cell–driven inflammation in lab tests and a mouse colitis model, a potential new therapeutic strategy relevant to IBD research and future drug...

The work links STAT4 — a gene locus associated with IBD — to Th17 pathogenic behavior and suppression of the anti-inflammatory cytokine IL-10, offering a possible mechanism by which STAT4 variants could worsen gut...

The study suggests a new experimental compound (7-KC delivered in mβCD) reduced colitis severity in an acute mouse model, which could inform early-stage therapeutic research targeting immune cell membrane properties.

People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...

This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.

If local complement Factor B helps the gut heal, it could change how researchers think about targeting complement in IBD — suggesting local regulation rather than systemic inhibition. That’s important because complement...

Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...

The abstract suggests a new AhR-targeting drug candidate, EQ504, may more strongly drive epithelial repair and barrier-related gene changes in lab models than an existing clinical AhR agonist, which could be relevant to...

People with pediatric‑onset Crohn’s disease on long‑term thiopurines may be at risk for severe EBV‑related complications like HLH; recognizing HLH early can be lifesaving. The case supports considering EBV screening...

Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Upadacitinib, and JAK inhibitor.

Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.

Pregnancy increases VTE risk, and people with IBD have additional thrombotic risk—understanding when to use thromboprophylaxis affects maternal safety. The review highlights uncertainty about applying Western-derived...

Caldera’s funding and Nasdaq listing mean the company can run phase 2 trials in ulcerative colitis and Crohn’s disease of a bispecific drug that targets two immune pathways. If successful, that approach could change...

A Phase 2/3 trial of guselkumab could expand biologic treatment options for people with moderate to severe ulcerative colitis if efficacy and safety are demonstrated. The trial’s use of standard clinical endpoints...

The trial explores a new way to boost regulatory T cells using low-dose IL-2, which could offer an alternative mechanism for people with Crohn's disease who haven't responded to existing therapies. It also links immune...

Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...

The study could improve prediction of who among first-degree relatives will develop Crohn's disease by combining blood biomarkers and lifestyle data, which may help earlier detection or targeted monitoring.

The trial tests a palatable elemental diet (mBIOTA) as a non-drug approach for treating outpatient IBD flares, which could reduce reliance on steroids and other medications if shown effective and tolerable.

A successful Phase 3 trial could add guselkumab — an IL-23–targeting biologic — as a treatment option for people with moderate to severe Crohn's disease, especially those who haven’t responded to prior therapies.

The study identifies TRPM5 in CD4 T cells as a modulator of T cell activation and intestinal inflammation in a mouse colitis model, which could help researchers exploring new immune-pathway targets for IBD.

The paper suggests that HRQoL and family functioning may be similar across disease types and common treatment approaches in children with IBD, but emotional health and parental worry remain areas needing attention.

Depressive symptoms are common in IBD and can worsen quality of life and disease management; non-drug options that may improve mood are especially relevant for patients seeking adjunctive or accessible therapies.

Cure8 could only read part of this source from newsbytesapp.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease.

This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...

This DailyMed entry is an official FDA drug-label record describing indications, dosing, and safety information for sulfasalazine—an older prescription medication still used in ulcerative colitis. Updated label details...

Cure8 found this source from aero-news.net, but the page could not be read reliably yet. It is tagged for Community and awareness. Open the original article for the full details.

If confirmed, αvβ6 autoantibodies could help identify people at higher risk for ulcerative colitis and point to a new mechanism (blockade of epithelial TGF‑β activation) that contributes to mucosal inflammation.

The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.

This study suggests that boosting Nrf2 activity in CD4+ T cells can reduce inflammatory Th1/Th17 responses and increase regulatory T cells, which may help control colonic inflammation in ulcerative colitis.

The study identifies a new molecular mechanism (CTSH citrullination) that appears to drive NETs formation and worsen colitis in mice, which could point toward future therapies targeting PAD4–CTSH–NETs pathways. That...

The study suggests chronic gut inflammation can cause measurable brain inflammation and neuronal dysfunction in an IBD model, and that creatine supplementation prevented those changes — a potential neuromodulatory...

This research suggests a common environmental contaminant (6PPD-quinone from tire rubber) can disrupt lipid metabolism and mitochondrial function in human colon cells and increase inflammatory signals linked to IBD.

People with IBD may be interested because the review identifies polysaccharides from traditional Chinese medicine as a potential source of new therapies that act on gut microbes, the intestinal barrier, and immune...

If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...

Cure8 could only read part of this source from Перспективи та інновації науки, so this card uses cautious topic tags instead of a full summary. It is tagged for Complications.

Cure8 could only read part of this source from Перспективи та інновації науки, so this card uses cautious topic tags instead of a full summary. It is tagged for Microbiome and Research and clinical trials.

Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...

The study points to a new local mechanism—ferroportin in colon macrophages—that links iron handling, the microbiome, and mucosal healing. If validated, this could lead to targeted treatments that help healing without...

The paper identifies Siglec‑E as an immune brake that limits colitis severity and colitis‑associated tumor development in mice, connecting an immune‑regulatory pathway to inflammation‑driven colorectal cancer risk—an...

The paper identifies a biologic pathway that links epithelial AhR signaling to NK cell–mediated tumor surveillance in the colon. For people with IBD, mechanisms that increase immune escape could relate to...